Nebivolol Ratiopharm (Nebivolol Hydrochloride)

• Nebivolol is a selective β1‑adrenergic blocker used in cardiovascular conditions.
• Hypertension: lowers systemic blood pressure by reducing cardiac output and promoting vasodilation.
• Heart failure: improves left‑ventricular systolic function and reduces symptoms in chronic heart failure.
• Left ventricular systolic dysfunction: supports cardiac performance and may delay disease progression.

• Nebivolol Hydrochloride selectively antagonizes β1‑adrenergic receptors, decreasing heart rate and myocardial contractility. In addition, it stimulates endothelial nitric oxide synthase, leading to nitric‑oxide‑mediated vasodilation, which together lower peripheral resistance and blood pressure without significant β2‑blockade.

Nebivolol is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Headache: mild to moderate intensity.
• Dizziness or light‑headedness, especially on standing.
• Fatigue or tiredness.
• Nausea or mild gastrointestinal upset.
• Bradycardia: heart rate slower than normal.
• Peripheral edema: swelling of ankles or feet.

Serious or Rare Side Effects

• Severe bradycardia or heart block requiring medical attention.
• Marked hypotension leading to fainting.
• Bronchospasm in patients with asthma or COPD.
• Allergic reactions such as rash, itching, or angio‑edema.
• Hepatic dysfunction with elevated liver enzymes.
• Worsening heart failure symptoms.

• Before initiating therapy, clinicians should assess cardiovascular status and comorbid conditions.
• Monitor blood pressure: ensure adequate control without excessive drop.
• Assess cardiac function: especially in patients with existing heart failure.
• Use caution in asthma/COPD: β‑blockade may precipitate bronchospasm.
• Adjust dose in renal/hepatic impairment: consider reduced clearance.
• Avoid abrupt discontinuation: taper to prevent rebound hypertension.
• Store below 25°C: keep in the original pack, protect from moisture.

Nebivolol may interact with several drug classes; careful review is advised.

Major Interactions (Avoid)

• Combined use with other β‑blockers: risk of excessive bradycardia.
• Calcium channel blockers verapamil or diltiazem: may increase plasma levels.
• Potent CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): can raise nebivolol concentrations.
• Clonidine withdrawal: may cause severe hypertension.
• Antihypertensive agents causing additive hypotension.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or ARBs: monitor for enhanced blood pressure reduction.
• Diuretics: watch for electrolyte disturbances and volume depletion.
• NSAIDs: may blunt antihypertensive effect.
• Antiarrhythmic drugs (e.g., amiodarone): monitor cardiac rhythm.
• Other antihypertensives: adjust dose as needed.